The present invention relates to heterocyclic compounds (e.g., compounds described by Formula (I)) and pharmaceutically acceptable salts thereof. The invention also features pharmaceutical compositions that include these compounds and their use in therapy for treating conditions in which necroptosis is likely to play a substantial role. The heterocyclic compounds described herein can also achieve improved activity and selectivity towards RIP1 and/or RIP3.
-
Page/Page column 52
(2014/09/29)
Compounds and methods for modulation of estrogen receptors
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-β over ER-α. Methods are disclosed for modulating ER-β in cell and/o
-
(2008/06/13)
PYRROLO-TRIAZINE ANILINE COMPOUNDS USEFUL AS KINASE INHIBITORS
-
-
Page/Page column 117
(2008/06/13)
Synthesis of Some 1-(3'-Substituted-4'-methylbenzyl)-2-substituted-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolines
N--4'-methyl-3'-nitrophenylacetamide (4) on cyclisation with POCl3-CH3CN followed by catalytic reduction of the resulting 1-(4'-methyl-3'-nitrobenzyl)-6,7-dimethoxy-3,4-dihydroisoquinoline (6) gives 1-(3'-amino-4'-methylbenzyl)-6,
Prasad, Rajendra,Bhaduri, A. P.
p. 247 - 249
(2007/10/02)
More Articles about upstream products of 54941-44-5